Ticker: TSX – TOS
Shares Outstanding: 83,242,989
Company at Inflection Point with Commercial Rollout of Breakthrough Medical Device Sterilization Technology
QUÉBEC CITY, Sept. 22, 2015 /CNW Telbec/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company") an innovator in sterilization technology for medical devices in healthcare settings, has engaged Liolios Group to lead a new strategic investor relations and financial communications program.
"The recent months have been highly transformative for TSO3, following the long-anticipated FDA 510(k) clearance of our flagship STERIZONE® VP4 low temperature sterilizer last December," said TSO3 President and CEO, Ric Rumble. "With our product's superior claims over the competition and strong initial sales channels in place, we have seen the creation of a rapidly expanding opportunity pipeline. We have received initial orders and are preparing to officially open our new distribution and customer support facility based in South Carolina in October. The Company has clearly entered the commercialization stage of its development."
"Having reached this pivotal point in our growth trajectory, we believe our shareholders will benefit from an experienced team of financial communication professionals to help us navigate the capital markets and generate greater awareness of TSO3 in the investment community," continued Mr. Rumble. "Liolios Group brings a proven record of helping emerging growth companies like ours, enhance shareholder value by delivering the right message to the right audience and establishing high-quality, long-term relationships with influential members of the financial community."
Over the course of the next several weeks, Liolios Group will work closely with TSO3 management to develop and execute a comprehensive capital markets strategy. Activities will include messaging and corporate positioning, strategic advisory and introductions to analysts, investors and other key influencers across the financial community. Liolios Group will also schedule a number of road shows and financial conferences for management over the next several months.
For additional information about TSO3, contact Liolios Group at (949) 574-3860 or email [email protected].
About the STERIZONE® VP4 low temperature sterilizer
The STERIZONE® VP4 Sterilizer developed by TSO3 is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for a cost effective and error-free sterilization process. TSO3's unique Dynamic Sterilant Delivery SystemTM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75 lb load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.
More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section: http://www.tso3.com/en/products/sterizone-vp4/
Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO3, visit the Company's Web site at www.tso3.com.
About Liolios Group
Liolios Group, Inc. is a highly selective and comprehensive investor relations firm specializing in small-cap companies. The firm aims to deliver superior performance in corporate messaging and positioning, investor awareness, analyst and financial press coverage, and capital attraction. Founded in 1999, Liolios Group executives have extensive experience in finance and investments, and represent clients in a wide range of industries, including technology, digital media, consumer/internet retail, healthcare/life sciences, natural resources and business services. For more information about Liolios Group, visit www.liolios.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SOURCE TSO3 Inc.
For further information: Company Contact: R.M. (Ric) Rumble, President and CEO, 418 651-0003, Email: [email protected]; Investor Relations: Chris Tyson, Liolios Group, Inc., 949 574-3860, [email protected]